Study of YK012 in B-cell Acute Lymphoblastic Leukemia

Summary

The purpose of this study is to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of YK012 administered as monotherapy in participants with B-cell acute lymphoblastic leukemia (B-ALL).

Timeline

Start

2024-09-25

Primary completion

2026-12-31

Completion

2027-06-30

Drugs

Indications